Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | FABP2 | P12104 | 1/20 | 0.47 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19824483 | 0.87 | KIF11 (0.56) | PTGS1MEN1PTGS2KMT2ATSHR | |
| SCHEMBL19824426 | 0.85 | BACE1 (0.49) | PTGS1MEN1PTGS2KMT2ATSHR | |
| SCHEMBL11445119 | 0.84 | BACE1 (0.47) | TSHRPDK2BACE1 | |
| SCHEMBL27709190 | 0.82 | PTGS1 (0.46) | PTGS1MEN1PTGS2KMT2ATSHR | |
| SCHEMBL11152579 | 0.82 | TSHR (0.43) | PTGS1MEN1PTGS2KMT2ATSHR | |
| SCHEMBL3776828 | 0.82 | LMNA (0.47) | PTGS1MEN1PTGS2KMT2ATSHR | |
| SCHEMBL10829222 | 0.82 | PTGS1 (0.42) | PTGS1MEN1PTGS2KMT2ATSHR | |
| SCHEMBL13802305 | 0.82 | PTGS1 (0.46) | PTGS1MEN1PTGS2KMT2ATSHR | |
| Desmethylflurbiprofen SCHEMBL538938 | 0.82 | PTGS1 (0.56) | PTGS1MEN1PTGS2KMT2ATSHR | |
| SCHEMBL35774 | 0.81 | TSHR (0.50) | TSHRPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025070077-A1 | CURABLE RESIN COMPOSITION, CURED ARTICLE, AND OPTICAL WAVEGUIDE | DIC株式会社 | 2025-04-03 | — | — | WO | disclosed |
| US-20240050438-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | ATHENEX, INC. | 2024-02-15 | — | — | US | disclosed |
| US-20220119347-A1 | BIARYL COMPOSITIONS IN COMBINATION WITH TAMOXIFEN AND METHODS FOR MODULATING A KINASE CASCADE | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2022-04-21 | — | — | US | disclosed |
| US-20210252008-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2021-08-19 | — | — | US | disclosed |
| EP-3275973-B1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORP (JP) | 2019-12-18 | — | — | EP | disclosed |
| US-10196357-B2 | Biaryl compositions and methods for modulating a kinase cascade | ATHENEX, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-3275973-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-9828338-B2 | Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170196874-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | OAKTREE FUND ADMINISTRATION, LLC | 2017-07-13 | — | — | US | disclosed |
| US-9655903-B2 | Compositions and methods of treating cell proliferation disorders | ATHENEX, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| WO-2008002676-A9 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS LLC (US) | 2008-07-03 | — | — | WO | disclosed |
| CN-101184734-A | Compounds and methods for treating cell proliferation disorders | KINEX PHARMACEUTICALS LLC (US) | 2008-05-21 | — | — | CN | disclosed |
| WO-2008002676-A2 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2008-01-03 | — | — | WO | disclosed |
| US-7300931-B2 | Compositions for treating cell proliferation disorders | KINEX PHARMACEUTICALS, LLC (US) | 2007-11-27 | — | — | US | disclosed |
| EP-1836169-A2 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS | Kinex Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070197783-A1 | Compositions and methods of treating cell proliferation disorders | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070015752-A1 | Biaryl compositions and methods for modulating a kinase cascade | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-01-18 | — | — | US | disclosed |
| US-20060160800-A1 | Morpholino-2-[6-(2-Ethoxy-phenyl)-pyridin-3-yl]-benzyl)-acetamide compound; as anti-proliferative agents, for treating mammals | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2006-07-20 | — | — | US | disclosed |
| WO-2006071960-A2 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS | KINEX PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
| CN-1126473-A | Carbazole derivatives with 17,20-lyase-inhibiting activity | GLAXO GROUP LTD (GB) | 1996-07-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119347-A1 | BIARYL COMPOSITIONS IN COMBINATION WITH TAMOXIFEN AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K2, MAP3K6, MAP3K8 | PTGS1 1638/4885MEN1 3706/4885PTGS2 1229/4885 |
| US-20070015752-A1 | Biaryl compositions and methods for modulating a kinase cascade | MAP3K3, MAP3K2, MAP3K20 | PTGS1 3137/4885MEN1 3058/4885PTGS2 2653/4885 |
| US-20060160800-A1 | Morpholino-2-[6-(2-Ethoxy-phenyl)-pyridin-3-yl]-benzyl)-acetamide compound; as anti-proliferative agents, for treating mammals | MKI67, PCNA, CCAR2 | PTGS1 1234/4885MEN1 1974/4885PTGS2 902/4885 |
| US-20240050438-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K3, MAP3K2, MAP3K20 | PTGS1 3137/4885MEN1 3058/4885PTGS2 2653/4885 |
| US-20170196874-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K3, MAP3K2, MAP3K20 | PTGS1 3137/4885MEN1 3058/4885PTGS2 2653/4885 |
| US-10196357-B2 | Biaryl compositions and methods for modulating a kinase cascade | MAP3K2, MAP3K3, MAP3K6 | PTGS1 2639/4885MEN1 2946/4885PTGS2 1967/4885 |
| US-20210252008-A1 | BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K3, MAP3K2, MAP3K20 | PTGS1 3137/4885MEN1 3058/4885PTGS2 2653/4885 |
| US-20070197783-A1 | Compositions and methods of treating cell proliferation disorders | MKI67, CCNC, CCNA1 | PTGS1 363/4885MEN1 614/4885PTGS2 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.